...Thank you, Jessica. It's wonderful to be given this opportunity a year later. I think for us, the vision has always been to be a commercial company. And we're progressing towards that, with 050, our lead product candidate, progressing through the Phase 2 trial. And we're now looking forward to engaging with regulators in the beginning of the year on the design of the Phase 3 registration trial. That's an exciting place. We just announced a few months ago that we've got our Phase 2 012 trial started. And we've got our second 012 trial starting in this half of the year, whereby we'll be able to have some biomarker data next year. And just a few weeks ago in our quarterly, we announced a new product candidate that increases skeletal muscle and bone for Duchenne's Muscular Dystrophy. I think it's a pretty exciting time where we've got programs that are maturing, getting to registration trials, and a pipeline that's constantly filling -- coming forward with new product candidates and diversifying...
